{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-070173","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-06-03T21:14:06+00:00","discovered_at":"2026-06-03T21:16:00.208694+00:00","generated_at":"2026-06-03T21:18:03.582116+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares","bullets":["Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.","Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.","New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.","Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.","Net proceeds from the exercise will be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-070173","json":"https://secwatch.observer/filing/0001104659-26-070173.json","markdown":"https://secwatch.observer/filing/0001104659-26-070173.md","text":"https://secwatch.observer/filing/0001104659-26-070173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:18:03.582116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ff5425b6f0b3715e56a2d29abfae4c967954775","claim":"Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).","evidence_excerpt":"On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a holder of its existing common stock warrants"},{"label":"Value","value":"$1,861,920.00"},{"label":"Effective","value":"2026-06-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}